Synairgen PLC (LON:SNG), the respiratory drug discovery and development company, said it has completed recruitment of hospitalised patients with coronavirus (COVID-19) for its clinical trial of SNG001.
Synairgen's clinical trial in COVID-19 patients (SG016) is a double-blind, placebo-controlled trial. The 220 patient trial comprises 100 patients initiated in hospitals and 120 patients initiated in the home setting.
The patients participating in the hospital setting have been recruited across a number of National Health Service (NHS) trusts. The trial has been adopted by the NIHR Respiratory Translational Research Collaboration, a union of leading centres in respiratory medicine in the UK.
Synairgen said a successful outcome for the trial would provide valuable information for the continued development of SNG001, an inhaled formulation of interferon-beta-1a, in COVID-19 patients.
Results from the hospital setting are expected in July 2020, as previously announced.
#SNG Synairgen CEO details expansion of key coronavirus trial to patients in home https://t.co/BSXHnZIxjM via @proactive_uk
— adymctavish49 (@adymctavish49) May 26, 2020
“A successful outcome from this trial could be a critical step towards strengthening the fight against the COVID-19 pandemic,” said Richard Marsden, the chief executive officer of Synairgen in a statement.
Shares in Synairgen, which started the year trading at around 5.94p, eased 0.7% to 45.7p in early deals.